BACKGROUND: Early diagnosis and supportive therapy are important in primary systemic amyloidosis (AL). In 1986, a national network was started in Italy to increase the awareness of medical professionals, achieve early diagnoses, and provide locally qualified care. We compared the AL patient population observed at a referral center, Mayo Clinic, with that recruited through the Italian network. METHODS: All the patients diagnosed with AL between 1988 and 1998 at Mayo Clinic or in any of the centers of the Italian Amyloidosis Study Group were included. FINDINGS: The median survival of Italian patients was 30 months versus 12 months in the Mayo cohort (Por=2 organs involved, and treatment with alkylating agents independently predicted sur...
Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid...
The survivorship needs of patients with light-chain (AL) amyloidosis are complex, as is the diagnosi...
BACKGROUND AND OBJECTIVES: Light chain (AL) and secondary (AA) amyloidosis usually present as a syst...
Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in...
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into in...
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into in...
BACKGROUND: Amyloidosis has been a mystery for centuries, but research of the last decennia has clar...
Abstract The recent decades have ushered in considerable advancements in the diagnosis and treatment...
BACKGROUND: Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder character...
Background: Primary systemic light-chain (AL) amyloidosis is characterized by the deposition of immu...
Background: Amyloidosis is a heterogeneous disease caused by deposition of amyloid fibrils in organs...
: The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to hematologis...
Primary systemic light chain amyloidosis (AL) is a rare monoclonal plasma cell disorder. Much resear...
BACKGROUND: Few data are available from large population-based studies on survival and renal outcome...
International audienceBackgroundAmyloidosis is a complex group of rare conditions. For patients, amy...
Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid...
The survivorship needs of patients with light-chain (AL) amyloidosis are complex, as is the diagnosi...
BACKGROUND AND OBJECTIVES: Light chain (AL) and secondary (AA) amyloidosis usually present as a syst...
Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in...
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into in...
Systemic amyloidosis is a heterogeneous group of diseases associated with protein misfolding into in...
BACKGROUND: Amyloidosis has been a mystery for centuries, but research of the last decennia has clar...
Abstract The recent decades have ushered in considerable advancements in the diagnosis and treatment...
BACKGROUND: Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder character...
Background: Primary systemic light-chain (AL) amyloidosis is characterized by the deposition of immu...
Background: Amyloidosis is a heterogeneous disease caused by deposition of amyloid fibrils in organs...
: The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to hematologis...
Primary systemic light chain amyloidosis (AL) is a rare monoclonal plasma cell disorder. Much resear...
BACKGROUND: Few data are available from large population-based studies on survival and renal outcome...
International audienceBackgroundAmyloidosis is a complex group of rare conditions. For patients, amy...
Amyloidosis is a heterogeneous group of disorders associated with pathological deposition of amyloid...
The survivorship needs of patients with light-chain (AL) amyloidosis are complex, as is the diagnosi...
BACKGROUND AND OBJECTIVES: Light chain (AL) and secondary (AA) amyloidosis usually present as a syst...